Acquired von Willebrand syndrome: Is it an extremely rare disorder or do we see only the tip of the iceberg?

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 4, 2008, Pages 565-568

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; CORTICOSTEROID; DESMOPRESSIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR;

ACQUIRED VON WILLEBRAND DISEASE; AUTOIMMUNE DISEASE; BLEEDING; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING TEST; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NOTE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN SECRETION; RARE DISEASE; VON WILLEBRAND DISEASE;

ANTIGENS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; DEAMINO ARGININE VASOPRESSIN; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 40949113577     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02917.x     Document Type: Note

References (36)

1. Federici AB. Acquired von Willebrand syndrome: An under- and misdiagnosed bleeding complication in patients with lympho- and myeloproliferative disorders. Semin Hematol 2006; 43: S48-58.
2. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-9.
3. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31: 806-12.
4. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE, Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: Data from a international registry. Thromb Haemost 2000; 84: 345-9.
5. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: A concise review. Am J Hematol 1997; 54: 139-45.
6. Tefferi A, Nichols WL. Acquired von Willebrand disease: Concise review of occurrence, diagnosis, pathogenesis and treatment. Am J Med 1997; 103: 536-40.
7. Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome - report of 10 cases and review of the literature. Haemophilia 1999; 5: 318-26.
8. Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: From pathophysiology to management. Thromb Haemost 2000; 84: 175-82.
9. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Hematol 2001; 14: 401-36.
10. Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002; 28: 227-38.
11. Mannucci PM, Lombardi R, Bader R, Horellou MH, Finazzi G, Besana C, Conard J, Samama M. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984; 64: 614-21.
12. van Genderen PJJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80: 495-8.
13. Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79: 38-44.
14. Federici AB, Berkowitz SD, Lattuada A, Mannucci PM. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 1993; 81: 720-5.
15. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort LM, Hoyer LW, Reisner HM, White GC II, eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995: 87-92.
16. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9: 303-8.
17. Noronha PA, Hruby MA, Maurer HS. Acquired von Willebrand disease in a patient with Wilms tumor. J Pediatr 1979; 95: 997-9.
18. Scott JP, Montgomery RR, Tubergen DG, Hays T. Acquired von Willebrand's disease in association with Wilm's tumor: Regression following treatment. Blood 1981; 58: 665-9.
19. Richard C, Sedano MC, Cuadrado MA, Recio M, Hermosa V, Zubizarreta A. Acquired von Willebrand's syndrome associated with hydatid disease of the spleen -disappearance after splenectomy. Thromb Haemost 1984; 52: 90-3.
20. Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasia after aortic valve replacement. Ann Intern Med 1986; 105: 54-7.
21. Weinstein M, Ware JA, Troll JH, Salzman EW. Changes in von Willebrand factor during cardiac surgery: Effect of desmopressin acetate. Blood 1988; 71: 1648-55.
22. Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS. Acquired von Willebrand disease in Wilms'tumor patients. J Clin Oncol 1992; 10: 422-7.
23. Facon T, Caron C, Courtin P, Wurtz A, Deghaye M, Bauters F, Mazurier C, Goudemand J. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. Br J Haematol 1992; 80: 488-94.
24. Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet 1996; 347: 689-90.
25. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, Steffan A, Ruggeri ZM. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290-5.
26. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goedemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-9.
27. Duran-Saurez JR, Pico M, Zuazu J, Cortes M, Monasterio J, Tringiner J. Acquired von Willebrand's disease caused by a chronic granulocytic leukemia. Br J Haematol 1981; 48: 173-5.
28. Tran-Thang C, Mannucci PM, Schneider P, Federici AB, Bachmann F. Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma. Br J Haematol 1985; 61: 307-14.
29. Murakawa M, Okamura T, Tsutsumi K, Tanoguchi S, Kamura T, Shibuya T, Harada M, Niho Y. Acquired von Willebrand's disease in association with essential thrombocythemia: Regression following treatment. Acta Haematol 1992; 87: 83-7.
30. Dalrymple-Hay M, Aitchison R, Collins R, Sekhar M, Colvin B. Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 1992; 14: 209-11.
31. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von Willebrand factor. Am J Hematol 1995; 49: 83-6.
32. Strauss RG, Stump DC, Henriksen RA. Hydroxyethyl starch accentuates von Willebrand's disease. Transfusion 1985; 25: 235-7.
33. Kreuz W, Linde R, Funk M, Meyer-Schrod R, Foll E, Nowak-Gottl U, Jacobi G, Vigh Z, Scharrer I. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335: 1350-1.
34. Conrad ME, Latour LF. Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy. Am J Hematol 1992; 41: 143-4.
35. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
36. Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66: 292-4.